Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

PARP Inhibitors in Ovarian Cancer: Experts Discuss Patient Cases and the Current Paradigm

Listen to Nicoletta Colombo, MD; Philipp Harter, MD, PhD; and Alexandra Leary, MD, PhD, discuss patient cases from a live CCO webinar on the current paradigm and long-term benefits of PARPi therapy in the treatment of ovarian cancer.
Nicoletta Colombo, MD
person default
Philipp Harter, MD, PhD
person default
Alexandra Leary, MD, PhD
Released: October 14, 2021

Nicoletta Colombo, MD; Philipp Harter, MD, PhD; and Alexandra Leary, MD, PhD, discuss patient cases from a live webinar on the current paradigm and long-term benefits of PARPi therapy in the treatment of ovarian cancer. Topics include:

  • Maintenance therapy in ovarian cancer
  • SOLO1, PRIMA, PAOLO-1 clinical data
  • Role of bevacizumab in treatment of ovarian cancer

Information on this Educational Activity

Faculty

Nicoletta Colombo, MD

Professor of Obstetrics and Gynecology
University of Milan-Bicocca
European Institute of Oncology
Milan, Italy

Nicoletta Colombo, MD, has disclosed that she has received consulting fees from AstraZeneca, BIOCAD, Clovis Oncology, Eisai, GlaxoSmithKline, ImmunoGen, Mersana, MSD/Merck, Novartis, Pfizer, Pharmamar, Roche, Takeda, and Tesaro.
Philipp Harter, MD, PhD

Deputy Director
Department of Gynecology and Gynecologic Oncology
Evang. Kliniken Essen-Mitte
Essen, Germany

Philipp Harter, MD, PhD, has disclosed that he has received funds for research support from AstraZeneca, Clovis, Genmab, GlaxoSmithKline, ImmunoGen, MSD/Merck, and Roche and consulting fees from AstraZeneca, Clovis, GlaxoSmithKline, ImmunoGen, MSD/Merck, Roche, and Stryker/Zailab.
Alexandra Leary, MD, PhD

Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Alexandra Leary, MD, PhD, has disclosed that she has received funds for research support from Ability, AstraZeneca, Clovis Oncology, GlaxoSmithKline, Merck Sharp & Dohme, and Tesaro and consulting fees from Ability, AstraZeneca, BIOCAD, Clovis Oncology, GlaxoSmithKline, Merck Serono, Merck Sharp & Dohme, Seattle Genetics, Tesaro, and Zentalis.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca

Related Content

Podcast episode with expert insights on important trial data for ovarian and endometrial cancers from the ESGO 2021 annual meeting, from Clinical Care Options (CCO)

Nicole Concin, MD, PhD Released: November 23, 2021

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2021, from Clinical Care Options (CCO)

Jubilee Brown, MD Nicole Concin, MD, PhD Bernard Doger de Spéville, MD, PhD Melissa M. Hardesty, MD, MPH person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD Ursula Matulonis, MD David Scott Miller, MD, FACOG, FACS Prof Isabelle Ray-Coquard, MD, PhD Released: November 15, 2021

Expert podcast on second-generation TRK inhibitors with Dr. George Demetri and Dr. Alexander Drilon, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue